




AWARDS, HONORS, AND GRANTS

November 14, 2022

Burak Awarded \$2.5M Tersus Life Sciences and NORCH Research Grants



Mehmet Furkan Burak, MD, of the Division of Endocrinology, Diabetes and Hypertension, was awarded a \$2.5 million research grant from Tersus Life Sciences for his clinical trial on the effects of pure palmitoleic acid on insulin sensitivity and lipogenesis, the formation of fat cells. He also received competitive renewal for a grant from the Nutrition Obesity Research Center at Harvard (NORCH), funding his research project "Identification of Immunometabolism Alterations in Adiponummary Axis to Treat Obesity-Related Asthma."

Burak's clinical trial will be the first translation to human studies of his lab's findings that palmitoleic acid, an omega-7 fatty acid, acts as a lipokine, improving insulin sensitivity and decreasing ectopic fat accumulation. His NORCH-funded research project on obesity-associated asthma investigates adipose tissue-related factors of immune cell metabolism.

More broadly, Burak leads a research group investigating and creating new therapeutic strategies for treating obesity-related immunometabolic diseases, such as diabetes, fatty liver disease and asthma.

Tersus Life Sciences is a bio-life science company dedicated to the research, development and commercialization of Provinal, an omega-7 fatty-acid blend developed by Tersus that has demonstrated lipid-lowering and anti-inflammatory effects. NORCH aims to provide its members the resources needed to conduct novel, high-quality research related to nutrition and obesity that can be translated into clinical care for patients and public health initiatives.